N-methyl Glycine (Sarcosine) for the Treatment of Obsessive Compulsive Disorder (OCD)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01031927 |
Recruitment Status
:
Completed
First Posted
: December 15, 2009
Last Update Posted
: December 29, 2009
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Obsessive Compulsive Disorder | Drug: N-methyl glycine | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 30 participants |
Allocation: | Non-Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Sarcosine as Primary or Adjunctive Therapy in Obsessive Compulsive Disorder: A Prospective, Open-label Study |
Study Start Date : | June 2007 |
Actual Primary Completion Date : | February 2009 |

-
Drug: N-methyl glycine
- Yale-Brown Obsessive Compulsive Scale [ Time Frame: week0, 2, 4, 6, 8, and 10 ]
- Hamilton Anxiety Rating scale [ Time Frame: week0, 2, 4, 6, 8, and 10 ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- a primary OCD according to DSM-IV
- at least 1 year's duration of OC symptoms and a minimum severity score of ≥16 on Yale-Brown Obsessive Compulsive Scale
- drug naïve at study entry or
- being free from psychotropic medication for at least 8 weeks at study entry,or
- inadequately responded to ongoing psychotropic medications at study entry (defined by a Y-BOCS score of ≧16 despite treatment with maximum tolerated dose of a SRI medication for at least 8 weeks)
Exclusion Criteria:
- patients with moderate to severe depression defined by a 21-item Hamilton Depression Rating Scale score of >17,
- a history of bipolar disorder, schizophrenia, schizoaffective disorder, or other psychosis as defined by DSM-IV, or if they were at significant risk of suicide, and
- with clinically significant organic disease including cardiovascular, hepatic, pulmonary, neurologic, metabolic, or renal disease

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01031927
Taiwan | |
China Medical University Hospital | |
Taichung, Taiwan |
Study Chair: | Guochuan E Tsai, MD, PhD | Department of Psychiatry, Harbor-UCLA Medical Center, California, U.S.A |
Responsible Party: | Po-Lun Wu, China Medical University Hospital |
ClinicalTrials.gov Identifier: | NCT01031927 History of Changes |
Other Study ID Numbers: |
DMR96-IRB-75 |
First Posted: | December 15, 2009 Key Record Dates |
Last Update Posted: | December 29, 2009 |
Last Verified: | December 2009 |
Keywords provided by China Medical University Hospital:
obsessive compulsive disorder sarcosine glycine transporter I NMDA receptor |
Additional relevant MeSH terms:
Disease Compulsive Personality Disorder Obsessive-Compulsive Disorder Pathologic Processes Personality Disorders Mental Disorders |
Anxiety Disorders Glycine Glycine Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs |